Nigerians throw naira notes around to show love: but it could land you in jail 
Extraordinary Vietnam fraud case exposes the inherent vulnerabilities of banks 
China’s new world order: looking for clues from Xi’s recent meetings with foreign leaders 
Whirlpool’s Stale Demand Led to 1,000 Job Cuts in the US 
Digital trade protocol for Africa: why it matters, what’s in it and what’s still missing 
The idea that US interest rates will stay higher for longer is probably wrong 
How cuts to marginal income tax could boost the UK’s stagnant economic growth 
How India’s economy has fared under ten years of Narendra Modi 
What if the Reserve Bank itself has been feeding inflation? An economist explains 
The yen plunges to 34-year low despite interest rate hike 
Binance Reassures Filipino Users Amid SEC App Removal Request, Urges Balanced Review by Google and Apple 
The Future of Gold Trading: Technological Advances and Market Predictions in the Philippines 
Samsung Biologics and Novartis International AG signed a contract manufacturing organization deal, and this was announced on Tuesday, June 7. The deal is worth $81 million.
According to The Korea Herald, the South Korean biotech company signed an intent letter for the CMO with the Swiss multinational pharmaceutical corporation. The agreement was announced via Samsung Biologics’ regulatory filing that also revealed that the companies signed the initial contract late last week.
Based on the report, the amount of the contract is equivalent to 6.41% of Samsung Biologics’ annual sales last year, which reached KRW1.57 trillion or around $1.25 billion. Then again, it was not mentioned which of Novartis’ biopharmaceutical products Samsung Biologics is producing under the CMO agreement.
The Korean biotech firm said that it would be releasing more deals in the future after both parties signed the main contract for their CMO partnership. The collab is said to be the first time Samsung Biologics is securing a deal from the Swiss pharmaceutical company.
“The letter of intent was the first contract between the two firms,” an official of Samsung Biologics stated. “We look forward to continuing to have cooperative relations through this deal in the future.”
The Korea Economic Daily reported that the latest deal increased Samsung Biologics’ total for CMO contracts to $400 million. The company has so far won orders from other multinational pharma firms such as GSK plc that is formerly known as GlaxoSmithKline plc, and Eli Lilly & Co. this year. In comparison, the firm was able to secure $1 billion worth of CMO contracts in 2021.
The South Korean CMO drugmaker obtained contracts from the top pharmaceutical firms in the world, including Bristol Myers Squibb, Roche, Johnson & Johnson, and Merck & Co. It was added that Samsung Biologics also has a contract with Gilead Sciences Inc. in the US.
Meanwhile, Samsung Biologics has been mostly manufacturing antibody treatments recently instead of cell-gene therapy (CGT). It has built up production facilities to make the drug substance for the messenger ribonucleic acid (mRNA)-based COVID-19 vaccines in its plant.
